

Niels HÃ,iby

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3040574/publications.pdf>

Version: 2024-02-01

179
papers

14,750
citations

38660

50
h-index

20307

116
g-index

182
all docs

182
docs citations

182
times ranked

14017
citing authors

#	ARTICLE	IF	CITATIONS
1	Antibiotic resistance of bacterial biofilms. International Journal of Antimicrobial Agents, 2010, 35, 322-332.	1.1	2,809
2	Inhibition of quorum sensing in <i>Pseudomonas aeruginosa</i> biofilm bacteria by a halogenated furanone compound. Microbiology (United Kingdom), 2002, 148, 87-102.	0.7	919
3	Strategies for combating bacterial biofilm infections. International Journal of Oral Science, 2015, 7, 1-7.	3.6	696
4	The clinical impact of bacterial biofilms. International Journal of Oral Science, 2011, 3, 55-65.	3.6	663
5	<i>Pseudomonas aeruginosa</i> biofilms in cystic fibrosis. Future Microbiology, 2010, 5, 1663-1674.	1.0	557
6	<i>Pseudomonas aeruginosa</i> tolerance to tobramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorum-sensing dependent. Microbiology (United Kingdom), 2005, 151, 373-383.	0.7	451
7	Mucoid conversion of <i>Pseudomonas aeruginosa</i> by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Microbiology (United Kingdom), 1999, 145, 1349-1357.	0.7	437
8	Garlic blocks quorum sensing and promotes rapid clearing of pulmonary <i>Pseudomonas aeruginosa</i> infections. Microbiology (United Kingdom), 2005, 151, 3873-3880.	0.7	381
9	Rapid necrotic killing of polymorphonuclear leukocytes is caused by quorum-sensing-controlled production of rhamnolipid by <i>Pseudomonas aeruginosa</i> . Microbiology (United Kingdom), 2007, 153, 1329-1338.	0.7	362
10	Tolerance and resistance of microbial biofilms. Nature Reviews Microbiology, 2022, 20, 621-635.	13.6	316
11	Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients. Advanced Drug Delivery Reviews, 2015, 85, 7-23.	6.6	250
12	Occurrence of Hypermutable <i>Pseudomonas aeruginosa</i> in Cystic Fibrosis Patients Is Associated with the Oxidative Stress Caused by Chronic Lung Inflammation. Antimicrobial Agents and Chemotherapy, 2005, 49, 2276-2282.	1.4	232
13	<i>Pseudomonas aeruginosa</i> recognizes and responds aggressively to the presence of polymorphonuclear leukocytes. Microbiology (United Kingdom), 2009, 155, 3500-3508.	0.7	207
14	The MexGHI-OpmD multidrug efflux pump controls growth, antibiotic susceptibility and virulence in <i>Pseudomonas aeruginosa</i> via 4-quinolone-dependent cell-to-cell communication. Microbiology (United Kingdom), 2005, 151, 1113-1125.	0.7	204
15	Recent advances in the treatment of <i>Pseudomonas aeruginosa</i> infections in cystic fibrosis. BMC Medicine, 2011, 9, 32.	2.3	201
16	MICROBIOLOGY OF LUNG INFECTIONS IN CYSTIC FIBROSIS PATIENTS. Acta Paediatrica, International Journal of Paediatrics, 1982, 71, 33-54.	0.7	196
17	Evolution and diversification of <i>Pseudomonas aeruginosa</i> in the paranasal sinuses of cystic fibrosis children have implications for chronic lung infection. ISME Journal, 2012, 6, 31-45.	4.4	184
18	<i>Pseudomonas aeruginosa</i> mutations in lasI and rhlI quorum sensing systems result in milder chronic lung infection. Microbiology (United Kingdom), 2001, 147, 1105-1113.	0.7	177

#	ARTICLE	IF	CITATIONS
19	Genetic adaptation of <i>Pseudomonas aeruginosa</i> during chronic lung infection of patients with cystic fibrosis: strong and weak mutators with heterogeneous genetic backgrounds emerge in <i>mucA</i> and/or <i>lasR</i> mutants. <i>Microbiology (United Kingdom)</i> , 2010, 156, 1108-1119.	0.7	171
20	Detection of N-acylhomoserine lactones in lung tissues of mice infected with <i>Pseudomonas aeruginosa</i> . <i>Microbiology (United Kingdom)</i> , 2000, 146, 2481-2493.	0.7	156
21	The immune response to chronic <i>Pseudomonas aeruginosa</i> lung infection in cystic fibrosis patients is predominantly of the Th2 type. <i>Apmsis</i> , 2000, 108, 329-335.	0.9	155
22	Environmental Heterogeneity Drives Within-Host Diversification and Evolution of <i>Pseudomonas aeruginosa</i> . <i>MBio</i> , 2014, 5, e01592-14.	1.8	153
23	Polymorphonuclear Leukocytes Restrict Growth of <i>Pseudomonas aeruginosa</i> in the Lungs of Cystic Fibrosis Patients. <i>Infection and Immunity</i> , 2014, 82, 4477-4486.	1.0	138
24	A short history of microbial biofilms and biofilm infections. <i>Apmsis</i> , 2017, 125, 272-275.	0.9	132
25	Results of Multiple Diagnostic Tests for <i>Mycobacterium avium</i> subsp. <i>paratuberculosis</i> in Patients with Inflammatory Bowel Disease and in Controls. <i>Journal of Clinical Microbiology</i> , 2000, 38, 4373-4381.	1.8	125
26	Impact of <i>Pseudomonas aeruginosa</i> quorum sensing on biofilm persistence in an in vivo intraperitoneal foreign-body infection model. <i>Microbiology (United Kingdom)</i> , 2007, 153, 2312-2320.	0.7	124
27	Chronic pulmonary disease with <i>Mycobacterium abscessus</i> complex is a biofilm infection. <i>European Respiratory Journal</i> , 2015, 46, 1823-1826.	3.1	120
28	Antibiofilm Properties of Acetic Acid. <i>Advances in Wound Care</i> , 2015, 4, 363-372.	2.6	118
29	Biofilms and host response – helpful or harmful. <i>Apmsis</i> , 2017, 125, 320-338.	0.9	118
30	Comparing the harmful effects of nontuberculous mycobacteria and Gram negative bacteria on lung function in patients with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2016, 15, 380-385.	0.3	111
31	Chronic <i>Pseudomonas aeruginosa</i> lung infection is more severe in Th ₂ responding BALB/c mice compared to Th ₁ responding C ₃ H/HeN mice. <i>Apmsis</i> , 1997, 105, 838-842.	0.9	110
32	Understanding bacterial biofilms in patients with cystic fibrosis: current and innovative approaches to potential therapies. <i>Journal of Cystic Fibrosis</i> , 2002, 1, 249-254.	0.3	109
33	Epidemiology of nontuberculous mycobacteria among patients with cystic fibrosis in Scandinavia. <i>Journal of Cystic Fibrosis</i> , 2015, 14, 46-52.	0.3	107
34	Urinary Tract Infections in Patients with Spinal Cord Lesions. <i>Drugs</i> , 2001, 61, 1275-1287.	4.9	97
35	Evolution of Antibiotic Resistance in Biofilm and Planktonic <i>Pseudomonas aeruginosa</i> Populations Exposed to Subinhibitory Levels of Ciprofloxacin. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	97
36	<i>Pseudomonas aeruginosa</i> cross-infection among patients with cystic fibrosis during a winter camp. , 2000, 29, 177-181.		92

#	ARTICLE	IF	CITATIONS
37	Nitrous Oxide Production in Sputum from Cystic Fibrosis Patients with Chronic <i>Pseudomonas aeruginosa</i> Lung Infection. PLoS ONE, 2014, 9, e84353.	1.1	86
38	Investigation of the algT operon sequence in mucoid and non-mucoid <i>Pseudomonas aeruginosa</i> isolates from 115 Scandinavian patients with cystic fibrosis and in 88 in vitro non-mucoid revertants. Microbiology (United Kingdom), 2008, 154, 103-113.	0.7	77
39	<i>Pseudomonas aeruginosa</i> alginate is refractory to Th1 immune response and impedes host immune clearance in a mouse model of acute lung infection. Journal of Medical Microbiology, 2003, 52, 731-740.	0.7	76
40	ANTIMICROBIAL CHEMOTHERAPY IN CYSTIC FIBROSIS PATIENTS. Acta Paediatrica, International Journal of Paediatrics, 1982, 71, 75-100.	0.7	75
41	Production of N-acyl-L-homoserine lactones by <i>P. aeruginosa</i> isolates from chronic lung infections associated with cystic fibrosis. FEMS Microbiology Letters, 2000, 184, 273-278.	0.7	73
42	Diagnosis of biofilm infections in cystic fibrosis patients. Apmis, 2017, 125, 339-343.	0.9	69
43	Retrospective Clinical Study of Hypersensitivity Reactions to Aztreonam and Six Other β -Lactam Antibiotics in Cystic Fibrosis Patients Receiving Multiple Treatment Courses. Clinical Infectious Diseases, 1991, 13, S608-S611.	2.9	68
44	Physiological levels of nitrate support anoxic growth by denitrification of <i>Pseudomonas aeruginosa</i> at growth rates reported in cystic fibrosis lungs and sputum. Frontiers in Microbiology, 2014, 5, 554.	1.5	68
45	<i>Staphylococcus aureus</i> Alters Growth Activity, Autolysis, and Antibiotic Tolerance in a Human Host-Adapted <i>Pseudomonas aeruginosa</i> Lineage. Journal of Bacteriology, 2014, 196, 3903-3911.	1.0	68
46	Reinforcement of the bactericidal effect of ciprofloxacin on <i>Pseudomonas aeruginosa</i> biofilm by hyperbaric oxygen treatment. International Journal of Antimicrobial Agents, 2016, 47, 163-167.	1.1	68
47	Early immune response in susceptible and resistant mice strains with chronic <i>Pseudomonas aeruginosa</i> lung infection determines the type of T-helper cell response. Apmis, 1999, 107, 1093-1100.	0.9	63
48	The LapG protein plays a role in <i>Pseudomonas aeruginosa</i> biofilm formation by controlling the presence of the CdrA adhesin on the cell surface. MicrobiologyOpen, 2015, 4, 917-930.	1.2	63
49	A personal history of research on microbial biofilms and biofilm infections. Pathogens and Disease, 2014, 70, 205-211.	0.8	60
50	Bactericidal effect of colistin on planktonic <i>Pseudomonas aeruginosa</i> is independent of hydroxyl radical formation. International Journal of Antimicrobial Agents, 2014, 43, 140-147.	1.1	56
51	Rapid development in vitro and in vivo of resistance to ceftazidime in biofilm-growing <i>Pseudomonas aeruginosa</i> due to chromosomal AE-lactamase. Apmis, 2000, 108, 589-600.	0.9	55
52	OligoG CF-5/20 Disruption of Mucoid <i>Pseudomonas aeruginosa</i> Biofilm in a Murine Lung Infection Model. Antimicrobial Agents and Chemotherapy, 2016, 60, 2620-2626.	1.4	52
53	Antibiotic penetration and bacterial killing in a <i>Pseudomonas aeruginosa</i> biofilm model. Journal of Antimicrobial Chemotherapy, 2015, 70, 2057-2063.	1.3	50
54	<i>P. aeruginosa</i> flow-cell biofilms are enhanced by repeated phage treatments but can be eradicated by phage-ciprofloxacin combination. Pathogens and Disease, 2019, 77, .	0.8	50

#	ARTICLE	IF	CITATIONS
55	IDENTIFICATION AND QUANTITATION OF PRECIPITINS AGAINST <i>PSEUDOMONAS AERUGINOSA</i> IN PATIENTS WITH CYSTIC FIBROSIS BY MEANS OF CROSSED IMMUNOELECTROPHORESIS WITH INTERMEDIATE GEL. <i>Acta Pathologica Et Microbiologica Scandinavica - Section B Microbiology and Immunology</i> , 1973, 81B, 298-308.	0.0	49
56	Some bacterial parameters influencing the neutrophil oxidative burst response to <i>Pseudomonas aeruginosa</i> biofilms. <i>Apmis</i> , 1992, 100, 727-733.	0.9	46
57	EPIDEMIOLOGY OF <i>PSEUDOMONAS AERUGINOSA</i> INFECTION IN PATIENTS TREATED AT A CYSTIC FIBROSIS CENTRE. <i>Acta Pathologica Microbiologica Scandinavica Section B Microbiology</i> , 1980, 88B, 125-131.	0.0	46
58	Sinus surgery can improve quality of life, lung infections, and lung function in patients with primary ciliary dyskinesia. <i>International Forum of Allergy and Rhinology</i> , 2017, 7, 240-247.	1.5	46
59	<i>Ginseng</i> treatment enhances bacterial clearance and decreases lung pathology in athymic rats with chronic <i>P. aeruginosa</i> pneumonia. <i>Apmis</i> , 1997, 105, 438-444.	0.9	45
60	The <i>dlt</i> genes play a role in antimicrobial tolerance of <i>Streptococcus mutans</i> biofilms. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 298-304.	1.1	45
61	Hyperbaric Oxygen Sensitizes Anoxic <i>Pseudomonas aeruginosa</i> Biofilm to Ciprofloxacin. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	44
62	Antibiotic therapy as personalized medicine – general considerations and complicating factors. <i>Apmis</i> , 2019, 127, 361-371.	0.9	44
63	<i>Pseudomonas aeruginosa</i> and <i>Burkholderia cepacia</i> infection in cystic fibrosis patients treated in Toronto and Copenhagen. , 1998, 26, 89-96.		43
64	Prospects for the Prevention and Control of Pseudomonal Infection in Children with Cystic Fibrosis. <i>Paediatric Drugs</i> , 2000, 2, 451-463.	1.3	40
65	New antimicrobials in the management of cystic fibrosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 49, 235-238.	1.3	40
66	Simultaneous sinus and lung infections in patients with primary ciliary dyskinesia. <i>Acta Oto-Laryngologica</i> , 2015, 135, 58-63.	0.3	40
67	Diffusion Retardation by Binding of Tobramycin in an Alginate Biofilm Model. <i>PLoS ONE</i> , 2016, 11, e0153616.	1.1	40
68	Bacterial evolution in PCD and CF patients follows the same mutational steps. <i>Scientific Reports</i> , 2016, 6, 28732.	1.6	38
69	<i>PSEUDOMONAS AERUGINOSA</i> INFECTION IN CYSTIC FIBROSIS. Relationship between mucoid strains of <i>Pseudomonas aeruginosa</i> and the humoral immune response. <i>Acta Pathologica Et Microbiologica Scandinavica - Section B Microbiology and Immunology</i> , 1974, 82B, 551-558.	0.0	37
70	Denitrification by cystic fibrosis pathogens – <i>Stenotrophomonas maltophilia</i> is dormant in sputum. <i>International Journal of Medical Microbiology</i> , 2015, 305, 1-10.	1.5	34
71	Increased bactericidal activity of colistin on <i>Pseudomonas aeruginosa</i> biofilms in anaerobic conditions. <i>Pathogens and Disease</i> , 2016, 74, ftv086.	0.8	34
72	Mechanisms of humoral immune response against <i>Pseudomonas aeruginosa</i> biofilm infection in cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2018, 17, 143-152.	0.3	34

#	ARTICLE	IF	CITATIONS
73	A systematic review of studies on the faecal microbiota in anorexia nervosa: future research may need to include microbiota from the small intestine. <i>Eating and Weight Disorders</i> , 2018, 23, 399-418.	1.2	33
74	Formation of <i>Pseudomonas aeruginosa</i> inhibition zone during tobramycin disk diffusion is due to transition from planktonic to biofilm mode of growth. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 564-573.	1.1	33
75	Anti-biofilm Approach in Infective Endocarditis Exposes New Treatment Strategies for Improved Outcome. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 643335.	1.8	32
76	IMMUNE COMPLEX MEDIATED TISSUE DAMAGE IN THE LUNGS OF CYSTIC FIBROSIS PATIENTS WITH CHRONIC PSEUDOMONAS AERUGINOSA INFECTION. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 1982, 71, 63-73.	0.7	31
77	The effect of short-term, high-dose oral N-acetylcysteine treatment on oxidative stress markers in cystic fibrosis patients with chronic <i>P. aeruginosa</i> infection – A pilot study. <i>Journal of Cystic Fibrosis</i> , 2015, 14, 211-218.	0.3	31
78	Serodiagnosis of <i>Mycobacterium abscessus</i> complex infection in cystic fibrosis. <i>European Respiratory Journal</i> , 2015, 46, 707-716.	3.1	30
79	The phenotypic evolution of <i>Pseudomonas aeruginosa</i> populations changes in the presence of subinhibitory concentrations of ciprofloxacin. <i>Microbiology (United Kingdom)</i> , 2016, 162, 865-875.	0.7	30
80	Microbiological and Immunological Studies in a Case of Human Melioidosis Diagnosed in Denmark. <i>Scandinavian Journal of Infectious Diseases</i> , 1982, 14, 271-275.	1.5	29
81	The evolutionary trajectories of <i>P. aeruginosa</i> in biofilm and planktonic growth modes exposed to ciprofloxacin: beyond selection of antibiotic resistance. <i>Npj Biofilms and Microbiomes</i> , 2020, 6, 28.	2.9	29
82	Strict Protective Isolation in Allogeneic Bone Marrow Transplantation: Effect on Infectious Complications, Fever and Graft Versus Host Disease. <i>Scandinavian Journal of Infectious Diseases</i> , 1987, 19, 91-96.	1.5	27
83	IgG subclass antibody responses to alginate from <i>Pseudomonas aeruginosa</i> in patients with cystic fibrosis and chronic <i>P. aeruginosa</i> infection. <i>Pediatric Pulmonology</i> , 1992, 14, 44-51.	1.0	27
84	EPIDEMIOLOGICAL INVESTIGATIONS OF THE RESPIRATORY TRACT BACTERIOLOGY IN PATIENTS WITH CYSTIC FIBROSIS. <i>Acta Pathologica Et Microbiologica Scandinavica - Section B Microbiology and Immunology</i> , 1974, 82B, 541-550.	0.0	27
85	IMMUNOLOGICAL CROSS-REACTION BETWEEN ANTIGEN Tp4 OF <i>TREPONEMA PALLIDUM</i> AND AN ANTIGEN COMMON TO A WIDE RANGE OF BACTERIA. <i>Acta Pathologica, Microbiologica, Et Immunologica Scandinavica Section B, Microbiology</i> , 1984, 92B, 183-188.	0.1	27
86	Diversity of metabolic profiles of cystic fibrosis <i>Pseudomonas aeruginosa</i> during the early stages of lung infection. <i>Microbiology (United Kingdom)</i> , 2015, 161, 1447-1462.	0.7	27
87	Studies on Hypersensitivity to Bacterial Antigens in Intrinsic Asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 1982, 37, 191-201.	2.7	26
88	Polyagglutinability Due to Loss of O-Antigenic Determinants in <i>Pseudomonas Aeruginosa</i> Strains Isolated from Cystic Fibrosis Patients. <i>Acta Pathologica, Microbiologica, Et Immunologica Scandinavica Section B, Microbiology</i> , 1985, 93B, 7-13.	0.1	26
89	Pandemics: past, present, future. <i>Apmis</i> , 2021, 129, 352-371.	0.9	25
90	HYPERGAMMAGLOBULINEMIC PURPURA IN CYSTIC FIBROSIS. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 1978, 67, 443-447.	0.7	24

#	ARTICLE	IF	CITATIONS
91	Ulcer bed infection. <i>Apmis</i> , 1998, 106, 721-726.	0.9	24
92	Anti- <i>Pseudomonas aeruginosa</i> IgY antibodies promote bacterial opsonization and augment the phagocytic activity of polymorphonuclear neutrophils. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1-10.	1.4	24
93	Adaptation of <i>Pseudomonas aeruginosa</i> to the chronic phenotype by mutations in the <i>algTmucABD</i> operon in isolates from Brazilian cystic fibrosis patients. <i>PLoS ONE</i> , 2018, 13, e0208013.	1.1	24
94	Hyperbaric oxygen treatment increases killing of aggregating <i>Pseudomonas aeruginosa</i> isolates from cystic fibrosis patients. <i>Journal of Cystic Fibrosis</i> , 2019, 18, 657-664.	0.3	24
95	Relationship Between Chemical Composition and Biological Function of <i>Pseudomonas aeruginosa</i> Lipopolysaccharide: Effect on Human Neutrophil Chemotaxis and Oxidative Burst. <i>Journal of Leukocyte Biology</i> , 1991, 49, 15-20.	1.5	23
96	S100A8/A9 is an important host defence mediator in neuropathic foot ulcers in patients with type 2 diabetes mellitus. <i>Archives of Dermatological Research</i> , 2016, 308, 347-355.	1.1	23
97	PSEUDOMONAS AERUGINOSA INFECTION IN CYSTIC FIBROSIS: Occurrence of Precipitating Antibodies against <i>Pseudomonas Aeruginosa</i> in Relation to the Concentration of Sixteen Serum Proteins and the Clinical and Radiographical Status of the Lungs. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 1974, 63, 843-848.	0.7	22
98	Lipopolysaccharide is present in immune complexes isolated from sputum in patients with cystic fibrosis and chronic <i>Pseudomonas aeruginosa</i> lung infection. <i>Apmis</i> , 1992, 100, 175-180.	0.9	22
99	Modelling of ciprofloxacin killing enhanced by hyperbaric oxygen treatment in <i>Pseudomonas aeruginosa</i> PAO1 biofilms. <i>PLoS ONE</i> , 2018, 13, e0198909.	1.1	21
100	PSEUDOMONAS AERUGINOSA INFECTION IN CYSTIC FIBROSIS. <i>Acta Pathologica Et Microbiologica Scandinavica Section C, Immunology</i> , 1977, 85C, 107-114.	0.0	20
101	Antimicrobial Activity of β -Peptide/2-Peptoid Lysine-Based Peptidomimetics Against Colistin-Resistant <i>Pseudomonas aeruginosa</i> Isolated From Cystic Fibrosis Patients. <i>Frontiers in Microbiology</i> , 2019, 10, 275.	1.5	19
102	Experimental immunization with <i>Pseudomonas aeruginosa</i> alginate induces IgA and IgG antibody responses. <i>Apmis</i> , 1991, 99, 1061-1068.	0.9	18
103	Identification of outer membrane Porin D as a vitronectin-binding factor in cystic fibrosis clinical isolates of <i>Pseudomonas aeruginosa</i> . <i>Journal of Cystic Fibrosis</i> , 2015, 14, 600-607.	0.3	18
104	<i>Pseudomonas aeruginosa</i> biofilm hampers murine central wound healing by suppression of vascular epithelial growth factor. <i>International Wound Journal</i> , 2018, 15, 123-132.	1.3	18
105	Adjunctive dabigatran therapy improves outcome of experimental left-sided <i>Staphylococcus aureus</i> endocarditis. <i>PLoS ONE</i> , 2019, 14, e0215333.	1.1	18
106	IMMUNE COMPLEXES IN CYSTIC FIBROSIS. <i>Acta Pathologica Et Microbiologica Scandinavica Section C, Immunology</i> , 1977, 85C, 57-64.	0.0	17
107	Urine lipoarabinomannan point-of-care testing in patients affected by pulmonary nontuberculous mycobacteria – experiences from the Danish Cystic Fibrosis cohort study. <i>BMC Infectious Diseases</i> , 2014, 14, 655.	1.3	17
108	Mouse Model of Burn Wound and Infection: Thermal (Hot Air) Lesion-Induced Immunosuppression. <i>Current Protocols in Mouse Biology</i> , 2017, 7, 77-87.	1.2	17

#	ARTICLE	IF	CITATIONS
109	Biofilms of <i>Mycobacterium abscessus</i> Complex Can Be Sensitized to Antibiotics by Disaggregation and Oxygenation. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	17
110	Chronic <i>Pseudomonas aeruginosa</i> Biofilm Infection Impairs Murine S100A8/A9 and Neutrophil Effector Cytokines – Implications for Delayed Wound Closure?. <i>Pathogens and Disease</i> , 2017, 75, .	0.8	16
111	CROSS-REACTIONS BETWEEN <i>BORDETELLA PERTUSSIS</i> AND TWENTY-EIGHT OTHER BACTERIAL SPECIES. <i>Acta Pathologica Microbiologica Scandinavica Section B Microbiology</i> , 1976, 84B, 395-400.	0.0	15
112	In vivo demonstration of <i>Pseudomonas aeruginosa</i> biofilms as independent pharmacological microcompartments. <i>Journal of Cystic Fibrosis</i> , 2020, 19, 996-1003.	0.3	15
113	Local IgA and IgG response to intratracheal immunization with <i>Pseudomonas aeruginosa</i> antigens. <i>Apmis</i> , 1992, 100, 87-90.	0.9	14
114	Effects of Chinese medicinal herbs on a rat model of chronic <i>Pseudomonas aeruginosa</i> lung infection. <i>Apmis</i> , 1996, 104, 350-354.	0.9	14
115	Autofluorescence in samples obtained from chronic biofilm infections – all that glitters is not gold. <i>Pathogens and Disease</i> , 2015, 73, .	0.8	13
116	Chronic urinary tract infections in patients with spinal cord lesions – biofilm infection with need for long-term antibiotic treatment. <i>Apmis</i> , 2017, 125, 385-391.	0.9	13
117	Secretory IgA response against <i>Pseudomonas aeruginosa</i> in the upper airways and the link with chronic lung infection in cystic fibrosis. <i>Pathogens and Disease</i> , 2017, 75, .	0.8	13
118	Immune Modulating Topical S100A8/A9 Inhibits Growth of <i>Pseudomonas aeruginosa</i> and Mitigates Biofilm Infection in Chronic Wounds. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1359.	1.8	13
119	Secretory IgA-mediated immune response in saliva and early detection of <i>Pseudomonas aeruginosa</i> in the lower airways of pediatric cystic fibrosis patients. <i>Medical Microbiology and Immunology</i> , 2019, 208, 205-213.	2.6	13
120	Optimization of colistin dosing regimen for cystic fibrosis patients with chronic <i>Pseudomonas aeruginosa</i> biofilm lung infections. <i>Pediatric Pulmonology</i> , 2019, 54, 575-580.	1.0	13
121	High levels of complement-activation capacity in sera from patients with cystic fibrosis correlate with high levels of IgG3 antibodies to <i>Pseudomonas aeruginosa</i> antigens and poor lung function. <i>Pediatric Pulmonology</i> , 1995, 20, 71-77.	1.0	12
122	Activation of pulmonary and lymph node dendritic cells during chronic <i>Pseudomonas aeruginosa</i> lung infection in mice. <i>Apmis</i> , 2016, 124, 500-507.	0.9	12
123	Lack of the Major Multifunctional Catalase KatA in <i>Pseudomonas aeruginosa</i> Accelerates Evolution of Antibiotic Resistance in Ciprofloxacin-Treated Biofilms. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	12
124	PRECIPITATING ANTIBODIES AGAINST <i>ESCHERICHIA COLI</i> , <i>BACTEROIDES FRAGILIS</i> SS. <i>THETA</i> AND <i>PSEUDOMONAS AERUGINOSA</i> IN SERUM FROM NORMAL PERSONS AND CYSTIC FIBROSIS PATIENTS, DETERMINED BY MEANS OF CROSSED IMMUNOELECTROPHORESIS. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 1979, 68, 495-500.	0.7	11
125	Antigenic analysis of <i>Pseudomonas aeruginosa</i> and <i>Pseudomonas cepacia</i> GroEL proteins and demonstration of a lipopolysaccharide-associated GroEL fraction in <i>P. aeruginosa</i> . <i>Apmis</i> , 1993, 101, 621-630.	0.9	11
126	Genome Sequence of <i>Pseudomonas aeruginosa</i> Strain DK1-NH57388A, a Stable Mucoid Cystic Fibrosis Isolate. <i>Genome Announcements</i> , 2016, 4, .	0.8	11

#	ARTICLE	IF	CITATIONS
127	Adhesion of <i>Yersinia enterocolitica</i> to human epithelial cell lines and to rabbit and human small intestinal tissue. <i>Apmis</i> , 1990, 98, 53-60.	0.9	10
128	Oropharyngeal Candidiasis in Palliative Care Patients in Denmark. <i>Journal of Palliative Medicine</i> , 2015, 18, 940-944.	0.6	10
129	Combination and nanotechnology based pharmaceutical strategies for combating respiratory bacterial biofilm infections. <i>International Journal of Pharmaceutics</i> , 2022, 616, 121507.	2.6	10
130	<i>Pseudomonas cepacia</i> Septicemia in Patients with Burns: Report of Two Cases. <i>Scandinavian Journal of Infectious Diseases</i> , 1985, 17, 63-66.	1.5	9
131	Cloning and nucleotide sequence comparison of the <i>groE</i> operon of <i>Pseudomonas aeruginosa</i> and <i>Burkholderia cepacia</i> . <i>Apmis</i> , 1995, 103, 113-123.	0.9	9
132	Azithromycin potentiates avian IgY effect against <i>Pseudomonas aeruginosa</i> in a murine pulmonary infection model. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106213.	1.1	9
133	Novel human <i>in vitro</i> vegetation simulation model for infective endocarditis. <i>Apmis</i> , 2021, 129, 653-662.	0.9	9
134	The <i>Legionella micdadei</i> flagellin: Expression in <i>Escherichia coli</i> K 12 and DNA sequence of the gene. <i>Apmis</i> , 1995, 103, 869-877.	0.9	8
135	Comparison of Amoxicillin/Clavulanate with Amoxicillin in Children and Adults with Chronic Obstructive Pulmonary Disease and Infection with <i>Haemophilus influenzae</i> . <i>Scandinavian Journal of Infectious Diseases</i> , 1988, 20, 517-524.	1.5	7
136	Experimental chronic <i>Pseudomonas aeruginosa</i> lung infection in rats. <i>Apmis</i> , 1995, 103, 367-374.	0.9	7
137	Synergistic effect of immunomodulatory S100A8/A9 and ciprofloxacin against <i>Pseudomonas aeruginosa</i> biofilm in a murine chronic wound model. <i>Pathogens and Disease</i> , 2020, 78, .	0.8	7
138	Primary ciliary dyskinesia patients have the same <i>P. aeruginosa</i> clone in sinuses and lungs. <i>European Respiratory Journal</i> , 2020, 55, 1901472.	3.1	7
139	Potential Advances of Adjunctive Hyperbaric Oxygen Therapy in Infective Endocarditis. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 805964.	1.8	7
140	Serological diagnosis of experimental <i>Enterococcus faecalis</i> endocarditis. <i>Apmis</i> , 1998, 106, 997-1008.	0.9	6
141	Evaluation of a bovine antibody test for diagnosing <i>Mycobacterium avium</i> complex in patients with cystic fibrosis. <i>Pediatric Pulmonology</i> , 2017, 52, 34-40.	1.0	6
142	Dynamics of a <i>Staphylococcus aureus</i> infective endocarditis simulation model. <i>Apmis</i> , 2022, 130, 515-523.	0.9	6
143	A Comparative Study of Amoxicillin and Pivampicillin in Persistent <i>Haemophilus influenzae</i> Infection of the Lower Respiratory Tract in Children with Chronic Lung Disease. <i>Scandinavian Journal of Infectious Diseases</i> , 1986, 18, 245-254.	1.5	5
144	Experimental studies of survival of anaerobic bacteria at 4°C and 22°C in two different transport systems. <i>Apmis</i> , 1992, 100, 1048-1052.	0.9	5

#	ARTICLE	IF	CITATIONS
145	CROSSED IMMUNOELECTROPHORETIC ANALYSIS OF <i>NEISSERIA MENINGITIDIS</i> ANTIGENS AND OF CORRESPONDING ANTIBODIES IN PATIENTS WITH MENINGOCOCCAL DISEASE. <i>Acta Pathologica Et Microbiologica Scandinavica Section C, Immunology</i> , 1978, 86C, 1-9.	0.0	5
146	IgG avidity to <i>Pseudomonas aeruginosa</i> over the course of chronic lung biofilm infection in cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2018, 17, 356-359.	0.3	5
147	Next generation microbiology and cystic fibrosis diagnostics. <i>Current Opinion in Pulmonary Medicine</i> , 2018, 24, 599-605.	1.2	5
148	<i>Pseudomonas aeruginosa</i> antibody response in cystic fibrosis decreases rapidly following lung transplantation. <i>Journal of Cystic Fibrosis</i> , 2020, 19, 587-594.	0.3	5
149	Autologous fibrin sealant co-delivered with antibiotics is a robust method for topical antibiotic treatment after sinus surgery. <i>Acta Oto-Laryngologica</i> , 2021, 141, 181-186.	0.3	5
150	Distinct contribution of hyperbaric oxygen therapy to human neutrophil function and antibiotic efficacy against <i>Staphylococcus aureus</i> . <i>Apmis</i> , 2021, 129, 566-573.	0.9	5
151	Animal models of chronic and recurrent <i>Pseudomonas aeruginosa</i> lung infection – significance of macrolide treatment.. <i>Apmis</i> , 2021, , .	0.9	5
152	THE SEROLOGY OF PSEUDOMONAS AERUGINOSA ANALYSED BY MEANS OF QUANTITATIVE IMMUNOELECTROPHORETIC METHODS. <i>Acta Pathologica Et Microbiologica Scandinavica Section C, Immunology</i> , 2009, 84C, 372-382.	0.0	4
153	ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA IN SERUM FROM NORMAL PERSONS AND PATIENTS COLONIZED WITH MUCOID OR NON-MUCOID PSEUDOMONAS AERUGINOSA: RESULTS OBTAINED BY CROSSED IMMUNOELECTROPHORESIS. <i>Acta Pathologica Et Microbiologica Scandinavica Section C, Immunology</i> , 1977, 85C, 142-148.	0.0	4
154	Adjunctive S100A8/A9 Immunomodulation Hinders Ciprofloxacin Resistance in <i>Pseudomonas aeruginosa</i> in a Murine Biofilm Wound Model. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 652012.	1.8	4
155	Crossed immunoelectrophoretic analysis of <i>Yersinia enterocolitica</i> serotype O:3 antigens. <i>Apmis</i> , 1988, 96, 306-314.	0.9	3
156	<i>STAPHYLOCOCCUS AUREUS</i> IN CYSTIC FIBROSIS: ANTIBIOTIC SENSITIVITY AND PHAGE TYPES DURING THE LATEST DECADE. <i>Acta Pathologica Microbiologica Scandinavica Section B Microbiology</i> , 1975, 83B, 219-225.	0.0	3
157	Antibody response against <i>Pseudomonas aeruginosa</i> and its relationship with immune mediators in the upper and lower airways of cystic fibrosis patients. <i>Pediatric Pulmonology</i> , 2020, 55, 959-967.	1.0	3
158	SARS-CoV-2 infection dynamics in Denmark, February through October 2020: Nature of the past epidemic and how it may develop in the future. <i>PLoS ONE</i> , 2021, 16, e0249733.	1.1	3
159	Maintaining normal lung function in children with cystic fibrosis is possible with aggressive treatment regardless of <i>Pseudomonas aeruginosa</i> infections. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2021, 110, 2607-2609.	0.7	3
160	Lactoferricin-inspired peptide AMC-109 augments the effect of ciprofloxacin against <i>Pseudomonas aeruginosa</i> biofilm in chronic murine wounds. <i>Journal of Global Antimicrobial Resistance</i> , 2022, 29, 185-193.	0.9	3
161	Phenotypes selected during chronic lung infection in cystic fibrosis patients: implications for the treatment of <i>Pseudomonas aeruginosa</i> biofilm infections. <i>FEMS Immunology and Medical Microbiology</i> , 2012, 66, 120-120.	2.7	2
162	Early IL-2 treatment of mice with <i>Pseudomonas aeruginosa</i> pneumonia induced PMN-dominating response and reduced lung pathology. <i>Apmis</i> , 2020, 128, 647-653.	0.9	2

#	ARTICLE	IF	CITATIONS
163	Microbiological findings in emergency department patients with sepsis identified by the Sepsis-3 criteria: a single-center prospective population-based cohort study. <i>International Journal of Emergency Medicine</i> , 2021, 14, 39.	0.6	2
164	Crossed immunoelectrophoretic analysis of <i>Flavobacterium meningosepticum</i> DNA hybridization groups I and II. <i>Apmis</i> , 1989, 97, 591-594.	0.9	1
165	<i>PSEUDOMONAS AERUGINOSA</i> INFECTION IN CYSTIC FIBROSIS. <i>Acta Pathologica Et Microbiologica Scandinavica - Section B Microbiology and Immunology</i> , 1974, 82B, 559-566.	0.0	1
166	THE SEROLOGY OF <i>PSEUDOMONAS AERUGINOSA</i> ANALYSED BY MEANS OF QUANTITATIVE IMMUNOELECTROPHORETIC METHODS. <i>Acta Pathologica Microbiologica Scandinavica Section B Microbiology</i> , 2009, 83B, 321-327.	0.0	1
167	THE SEROLOGY OF <i>PSEUDOMONAS AERUGINOSA</i> ANALYSED BY MEANS OF QUANTITATIVE IMMUNOELECTROPHORETIC METHODS. <i>Acta Pathologica Et Microbiologica Scandinavica Section C, Immunology</i> , 2009, 84C, 383-389.	0.0	1
168	<i>PSEUDOMONAS AERUGINOSA</i> INFECTION IN CYSTIC FIBROSIS. <i>Acta Pathologica Et Microbiologica Scandinavica Section C, Immunology</i> , 1977, 85C, 149-152.	0.0	1
169	QUANTITATIVE STUDIES ON IMMUNOLOGICALLY SPECIFIC AND NON-SPECIFIC ABSORPTION OF <i>PSEUDOMONAS AERUGINOSA</i> ANTIBODIES IN SERUM FROM CYSTIC FIBROSIS PATIENTS. <i>Acta Pathologica Et Microbiologica Scandinavica Section C, Immunology</i> , 1981, 89C, 185-192.	0.0	1
170	Lymphocyte responses to <i>Mycobacterium tuberculosis</i> and <i>Mycobacterium bovis</i> are similar between BCG-vaccinated patients with cystic fibrosis and healthy controls. <i>Journal of Cystic Fibrosis</i> , 2020, 19, 575-579.	0.3	1
171	<i>Pseudomonas aeruginosa</i> cross-infection among patients with cystic fibrosis during a winter camp. , 2000, 29, 177.		1
172	Murine burn lesion model for studying acute and chronic wound infections. <i>Apmis</i> , 2022, 130, 477-490.	0.9	1
173	THE SEROLOGY OF <i>PSEUDOMONAS AERUGINOSA</i> ANALYSED BY MEANS OF QUANTITATIVE IMMUNOELECTROPHORETIC METHODS. <i>Acta Pathologica Microbiologica Scandinavica Section B Microbiology</i> , 2009, 83B, 328-334.	0.0	0
174	THE SEROLOGY OF <i>PSEUDOMONAS AERUGINOSA</i> ANALYSED BY MEANS OF QUANTITATIVE IMMUNOELECTROPHORETIC METHODS. <i>Acta Pathologica Microbiologica Scandinavica Section B Microbiology</i> , 2009, 83B, 433-442.	0.0	0
175	EPIDEMIOLOGICAL MARKERS FOR <i>PSEUDOMONAS AERUGINOSA</i> . <i>Acta Pathologica Microbiologica Scandinavica Section B Microbiology</i> , 1975, 83B, 553-560.	0.0	0
176	NITROBLUE-TETRAZOLIUM (NBT) REDUCTION BY HUMAN PERIPHERAL NEUTROPHIL GRANULOCYTES IN THE PRESENCE OF BACTERIAL ANTIGENS. <i>Acta Pathologica Et Microbiologica Scandinavica Section C, Immunology</i> , 1975, 83C, 144-156.	0.0	0
177	Editorial comment. <i>Apmis</i> , 2019, 127, 385-385.	0.9	0
178	Further Commentary. <i>Pediatric Pulmonology</i> , 2020, 55, 23-23.	1.0	0
179	Adaptive Immune Response to <i>Mycobacterium abscessus</i> Complex (MABSC) in Cystic Fibrosis and the Implications of Cross-Reactivity. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 858398.	1.8	0